TQA3526, developed by Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (Nanjing, China), is a novel FXR developed for use in patients with NASH and/or PBC. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.